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Abstract 
Background: The aim of this triple‑blind placebo‑controlled parallel‑arm randomized clinical trial was to evaluate 
the clinical effects of Lactobacillus rhamnosus SP1 or azithromycin as an adjunct to scaling and root planing (SRP) in 
patients with stage III periodontitis.
Methods: Forty‑seven systemically healthy participants with stage III periodontitis were recruited. Following SRP, the 
participants were randomly assigned to one of three treatment modalities; (1) placebo (n = 15), (2) probiotics (n = 16) 
and (3) antibiotics‑azithromycin (n = 16). The participants were monitored at baseline, 3, 6, 9 and 12 months after 
therapy. Probing pocket depth (PPD), bleeding on probing (BOP), clinical attachment loss (CAL) and plaque accumula‑
tion (PI) were evaluated.
Results: All 47 participants completed the study. At 12 months, all groups showed significant improvements of PPD 
and PI (p < 0.012) irrespective of the treatment modality and without significant differences between the groups. Pro‑
biotics and azithromycin showed no added benefit in terms of CAL. While the placebo (p = 0.002) and the antibiotic‑
azithromycin (p = 0.002) group showed a significant reduction of BOP, only the placebo group revealed a significant 
reduction of CAL at 12 months follow‑up (p = 0.003). The number of sites and teeth with PPD ≥ 5, ≥ 6 and ≥ 7 mm 
were significantly reduced in all groups at 12 months follow‑up (p < 0.025) irrespective of the treatment regime and 
without significant differences between the groups.
Conclusion: The use of probiotics or azithromycin as an adjunct to SRP failed to provide additional benefits in the 
treatment of stage III periodontitis. The benefits of these two treatment regimes as an adjunct to SRP remain unclear.
Trial registration: NCT02839408, 10/28/2017, Clinicaltrial.gov.
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Background
Periodontitis is characterized by a microbially‐associated 
and host‐mediated inflammation resulting in the loss of 
periodontal attachment [1]. This is caused by a dysbiotic 
microbiome in the subgingival biofilm in a susceptible 
host. The gold standard treatment to manage periodonti-
tis is scaling and root planing (SRP) [2, 3]. This treatment 
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allows the removal of supra- and subgingival deposits, 
cementum or surface dentin that is rough, impregnated 
with calculus or contaminated with toxins or micro-
organisms [4]. However, SRP may also fail. This failure 
could be due to the presence of deep pockets and the 
ensuing difficulties during the instrumentation, includ-
ing the inaccessibility of certain areas such as furcations 
[5]. Therefore, patients with deep pockets, progressive 
or ‘active’ disease, or specific microbiological profile, can 
benefit from an antibiotic adjunctive therapy [6].
Systemic antibiotics have the advantage of reaching all 
oral surfaces and fluids, in addition to having the poten-
tial to reach periodontal pathogens that eventually invade 
the host’s tissue [7]. Azithromycin is a broad-spectrum 
bacteriostatic antibiotic [8] with immunomodulatory 
properties [9]. Due to its pharmacological properties 
azithromycin allows a once a day administration over 
3 or 5  days, thus increasing patient compliance [8] and 
limiting the side effects. Azithromycin as an adjunct to 
SRP significantly improves the efficacy of non-surgical 
periodontal therapy in terms of probing pocket depth 
(PPD) and bleeding on probing (BOP) reduction along 
with clinical attachment level  (CAL) gain [5, 7]. SRP in 
conjunction with antibiotics is nevertheless not always 
associated with superior clinical results. The frequent 
recolonization of treated sites by periodontopathogens, 
as well as microbial resistance emergency calls for new 
therapeutic approaches for managing periodontitis. One 
such approach is the use of probiotics [9].
Probiotics are “living microorganisms, mainly bacte-
ria, that are safe for human consumption and when taken 
in proper quantities may provide beneficial effects for 
the human health” [10]. The modes of action of probi-
otics are related to their ability to enhance mucosal bar-
rier, produce antimicrobial agents, compete and exclude 
pathogenic agents, and modulate immune response. 
Lactobacillus and Bifidobacterium are the most com-
mon genera of bacteria in probiotics [11, 12]. Lactobacil-
lus rhamnosus SP1 also known as L. rhamnosus GG, has 
been proposed as an adjunct to SRP, thanks to its ability 
to inhibit the growth of periodontopathogens through 
bacteriocins [13, 14], its resistance to environmental 
stress [15], its immunomodulatory effect [16–18] and 
its inability to influence the acidogenicity of the suprag-
ingival plaque [19]. However, the available evidence 
regarding the clinical effects of probiotics as an adjunct 
to scaling and root planing (SRP) is controversial. While 
some systematic reviews and narrative reviews [20] claim 
improved clinical outcomes, a recent systematic review 
concluded that probiotics do  not provide clear clinical 
benefits [21]. Thus, it remains unclear whether probiot-
ics have an added benefit to SRP, thereby preventing their 
wide use in clinical practice.
The aim of the present study was, therefore, to evaluate 
the clinical effect of L. rhamnosus SP1 or azithromycin in 
the treatment of patients with stage III periodontitis. The 
null hypothesis states that either probiotics or azithro-
mycin as an adjunct to SRP in stage III periodontitis, do 
not lead to superior clinical outcomes compared to those 
obtained with SRP alone.
Methods
Ethical guidelines
This trial started in June 2014 and finished in August 
2016. This triple-blind placebo-controlled parallel-
arm randomized clinical trial was performed following 
guidelines recognized by the Declaration of Helsinki, as 
revised in 2013 for experimentation involving human 
participants. The study was approved by the Local Ethical 
Committee of the Faculty of Dentistry at the University 
of Chile (Decision number: 2012/08). The present report 
adheres to Consolidated Standards of Reporting Tri-
als (CONSORT) guidelines and was registered in clini-
caltrial.gov (identifier no. NCT02839408). The protocol 
of the study was explained to all patients, and informed 
consent was obtained after explanation of the purpose, 
nature, risks and benefits of participating in this study. 
The study details have been reported elsewhere [22].
Patient selection criteria
Ninety-six volunteers were initially examined in the Fac-
ulty of Dentistry, University of Chile, of which 47 were 
included in the present study. Eligibility criteria for par-
ticipants were as follows: (a) adult patients—aged 35 or 
older; (b) self-reported ‘good health’, with an absence of a 
medical history of a chronic disease or taking medication 
known to affect periodontal disease; (c) non-institution-
alized male or female; (d) presence of a minimum of 14 
teeth (excluding third molars); (d) presence of at least 10 
posterior teeth (e) Presence of at least 5 teeth with peri-
odontal sites with PPD ≥ 5  mm and clinical attachment 
loss (CAL) ≥ 3  mm, BOP ≥ 20% and extensive radio-
graphically determined bone loss.
The exclusion criteria were as follows: (a) pregnancy 
or lactation; (b) having received any periodontal treat-
ment in the 6-month period before the study; (c) having 
received non-steroidal anti-inflammatory medication, 
antibiotics or probiotics therapy in the past 6  months 
(prior to study).
Randomization of the study participants
Eligible individuals were randomly (simple randomi-
zation) allocated to groups according to gender, age, 
and smoking status after the basal examination using a 
computer-generated list. All participants were enrolled 
to one of the three treatment  groups: (1) placebo 
Page 3 of 15Morales et al. BMC Oral Health           (2021) 21:12  
(SRP + azithromycin placebo + probiotic placebo), (2) 
probiotic (SRP + probiotic + azithromycin placebo) or 
antibiotic (SRP + azithromycin + probiotic placebo) 
group (Fig.  1). Concealed allocation was performed 
using opaque, sealed envelopes containing probiotics or 
antibiotics arranged by an appointed research assistant. 
For the purpose of maintaining full blinding throughout 
the study period, the randomization code and details of 
the study groups were held by a research assistant only 
from the day of recruitment and were not revealed until 
all data had been collected and analyzed.
Clinical assessment
Periodontal clinical parameters including probing 
pocket depth (PPD), bleeding on probing (BOP), clini-
cal attachment loss (CAL) and plaque index (PI) were 
evaluated at six sites in all teeth, excluding third molars 
using a manual probe (UNC probe; Hu-Friedy Mfg. 
Co. Inc., Chicago IL, USA). All measurements were 
conducted by one calibrated examiner (AM). Clinical 
examinations were performed at baseline, 3, 6, 9 and 
12 months after treatment.
Periodontal therapy
After baseline examinations, all patients received non-
surgical periodontal therapy. Scaling and root planing 
(SRP) per quadrant (4–6 sessions, by PC, RC and NS) were 
performed using an ultrasonic scaler (Cavitron, Dentsply, 
York, PA, USA) and Gracey curettes (Hu Friedy Mfg. Co. 
Inc., Chicago, IL, USA). Treatment included oral hygiene 
instructions, using a manual toothbrush. The patients 
started taking the placebo, probiotic or antibiotics after the 
last session of SRP. The Placebo group received probiotic 
placebo sachets and antibiotic placebo capsules. Probiotic 
group received probiotic sachets and antibiotic placebo 
capsules. Antibiotic group received antibiotic capsules 
and probiotic placebo sachets. Identical sachets were pre-
sented to patients. Individuals were instructed to dissolve 1 
sachet (Lactobacillus rhamnosus SP1 (2 × 107 colony form-
ing units/day) (Macrofood S.A., Santiago, Chile) or probi-
otic placebo sachets in 150 ml of water and ingest it once 
a day after brushing their teeth, for 3 months. Azithromy-
cin 500 mg (capsules) or antibiotic placebo capsules were 
ingested once a day for 5 days. Placebo sachets (probiotic 
placebo) and placebo capsules (antibiotic placebo) were 
identical in taste, texture, and appearance to the probiotic 
Fig. 1 Flow chart of the study design
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sachets and antibiotic capsules. Periodontal supportive 
therapy was performed every 3 months (by PC). The ther-
apy provided at the maintenance appointment included 
removal of plaque and calculus, utilizing curets, ultrasonic 
devices, and rubber cup low‐speed polish as suggested 
by the American Academy of Periodontology position 
paper [23]. Behavior modification (tobacco cessation, oral 
hygiene instruction, and systemic factor counseling) was 
performed based on patient findings.
Compliance and adverse reactions
All patients returned capsules with antibiotics or placebo 
at 6-week visits and probiotics or placebo sachets at 1, 2 
and 3-month visits. At every visit, patients received new 
sachets. In order to check the patient’s compliance, they 
were called by phone every week. In each control visit 
or phone call, the clinical examiner (AM) inquired after 
general health changes, use of mouth rinses, use of probi-
otic products and any adverse events.
Outcome variables
The primary outcome was the change in CAL. Sec-
ondary outcome variables were changes in PPD, PI 
and BOP, percentages of patients, teeth and sites with 
PPD ≥ 5  mm, ≥ 6  mm, ≥ 7  mm. Sub-analyses were per-
formed on CAL and PPD, taking into account the initial 
PPD. A pocket was considered moderate if its initial PPD 
was between 4 and 6 mm and deep if ≥ 7 mm. Changes or 
delta (∆) in clinical parameters (at subject level) from base-
line to 3, 6, 9 and 12  months were determined. “Pocket” 
closure was defined as mean and SD of percentage of 
sites going from PPD ≥ 4  mm to PPD ≤ 3  mm at 3- and 
12-months follow up [7]. “Risk for disease progression” was 
defined at the patient level according to Lang and Tonetti 
[24]. Low risk was defined as ≤ 4 sites with PPD ≥ 5 mm, 
moderate risk was defined as 5–8 sites with PD ≥ 5  mm, 
and high risk was defined as ≥ 9 sites with PD ≥ 5  mm 
[24]. The “need for additional periodontal treatment” was 
defined as persisting pockets ≥ 5 mm with BOP [25].
Statistical analysis
Sample size calculation was performed using CAL as the 
primary outcome variable. A significance level of α = 5% 
α and a power level of 80% was defined. Considering a 
difference ≥ 1 mm between groups in CAL changes and 
a standard deviation of 0.8  mm [26], 14 participants 
per group were necessary to detect potential differ-
ences. For all statistical evaluations, the patient was the 
unit of measurement. The Shapiro–Wilk test was used 
to test the normality of the data sets. Quantitative data 
were recorded as the mean value ± standard deviation 
(SD) or percentage (%). The inter-group differences were 
determined using Fisher’s exact test, Kruskall Wallis test 
and ANOVA depending on the distribution of the data. 
Intra-group differences in clinical parameters over time 
were determined by the Related Samples Friedman’s 
test (p < 0.05) and. The Bonferroni-corrected Wilcoxon 
signed-rank test and Bonferroni-corrected Mc Nemar 
test were used to evaluate the intragroup multiple com-
parisons (p < 0.0125 or p < 0.025). Effect Sizes (‘mean 
change’ divided by ‘standard deviation of the baseline val-
ues’) were calculated based on changes in clinical param-
eters from baseline to 3, 6, 9 and 12  months or from 
baseline to 3 and 12  months follow-up. The statistical 
analysis was performed using a statistical package (Stata-
Corp, College Station, TX, USA).
Results
Forty-seven patients were analyzed; 16 in the probiotic 
group, 16 in the antibiotic group and 15 in the placebo 
group. All participants completed the study period and 
complied with the study requirements (Fig.  1). Adverse 
events were observed in one participant from the anti-
biotic group (nausea). The periodontal diagnosis of all 
participants was Stage III Periodontitis generalized grade 
B. Demographic, medical and clinical characteristics 
are described in Table 1. No significant differences were 
found between groups at baseline (p > 0.05).
The mean CAL, PPD, BOP and PI values at baseline 
and at 3, 6, 9, and 12 months follow-up of all groups are 
presented in Table 1. All treatment groups showed a sig-
nificant reduction of PPD and PI at all timepoints, inter-
group comparison however revealed that there were no 
significant differences between the treatment modalities 
(p > 0.05) (Table 1). In terms of CAL, the probiotic group 
showed a significant reduction at 3- and 9-month follow-
ups whereas the antibiotic group showed a significant 
reduction at 3- and 6-month follow-ups. The placebo 
group on the other hand, showed a significant reduc-
tion of CAL at all time points (p < 0.0125). With respect 
to BOP, the antibiotic and placebo groups showed a sig-
nificant reduction at 3-, 6- and 12-month follow-ups 
(p < 0.0125) whereas the probiotic group did not exhibit 
any improvement at any time point (p > 0.05).
The magnitude of statistical changes (effect size) in 
all clinical parameters from baseline to 3-, 6-, 9- and 
12-month follow-up was similar in all treatment modalities 
(Table  1). Furthermore, inter-group comparison revealed 
no significant differences in the changes (∆) of any clinical 
parameter between the treatment groups (p > 0.05).
Moderate pockets (PPD = 4–6  mm) in the antibiotic 
group revealed an increase in CAL at 3  months and a 
significant reduction of PPD at 12  months. Moderate 
pockets also showed a significant reduction in PPD in the 
placebo group at 3- and 12-month follow up in placebo 
group (Table 2. All, p < 0.025).
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Table 2 Clinical attachment loss (CAL) and probing pocket depth (PPD) in moderate (4–6 mm) and deep sites (≥ 7 mm) 
at baseline, 3-months and 12-months follow up






















5.6 ± 0.6 6.0 ± 1.0 6.1 ± 1.2 0.0238 a > b 
(p = 0.1208)
0.4 ± 0.9 0.5 ± 0.9 0.4 ± 0.9 0.5 ± 0.9





5.9 ± 1.0 6.4 ± 1.3 6.4 ± 1.4 0.0018 a < b 
(p = 0.0171)
− 0.04 ± 0.7 0.5 ± 1.0 0.7 ± 0.9 0.5 ± 1.0





6.1 ± 1.3 6.0 ± 1.7 6.5 ± 1.6 0.0006 a > b 
(p = 0.7333)
0.7 ± 1.0 0.4 ± 1.0 − 0.04 ± 0.7 0.4 ± 1.0











8.4 ± 1.8 9.3 ± 2.0 10.8 ± 3.6 0.0498 a > b 
(p = 0.7127)
0.05 ± 0.9 0.8 ± 1.1 0.1 ± 1.7 1.6 ± 2.2





9.5 ± 2.1 10.4 ± 2.4 11.2 ± 1.7 0.0498 a > b 
(p = 0.6858)
0.09 ± 0.6 0.2 ± 0.6 0.2 ± 1.1 0.4 ± 1.1





9.5 ± 2.1 11.1 ± 2.0 10.6 ± 2.1 0.3386 a > b 
(p = 0.2489)
0.4 ± 1.5 0.4 ± 0.8 0.9 ± 2.9 0.8 ± 1.6











4.5 ± 0.3 4.4 ± 0.5 4.3 ± 0.3 0.0006 a > b 
(p = 0.1788)
− 0.2 ± 1.9 − 0.8 ± 1.4 − 0.06 ± 0.5 − 0.2 ± 0.4





4.5 ± 0.2 4.4 ± 0.3 4.3 ± 0.2 0.0040 a > b 
(p = 0.0287)
− 0.6 ± 0.8 − 0.8 ± 0.7 − 0.2 ± 0.2 − 0.2 ± 0.2





4.6 ± 0.3 4.2 ± 0.2 4.2 ± 0.3 0.0280 a > b 
(p = 0.0007)
− 1.4 ± 0.9 − 1.3 ± 1.2 − 0.4 ± 0.2 − 0.4 ± 0.3
a > c 
(p = 0.0012)
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At 12 months follow-up, 80.3%, 77.8% and 77.2% of the 
baseline moderate pockets (PPD = 4–6  mm) presented 
a PPD ≤ 3  mm in the probiotic, antibiotic and placebo 
group respectively, without significant differences between 
the groups (p > 0.05) (Table  3). With respect to the base-
line deep pockets (PPD > 7  mm), 42.4%, 41.7% and 38.8% 
of these pockets presented a PPD ≤ 3  mm, and 47%, 50% 
and 45.9% presented PPD = 4–6  mm, without significant 
between the treatment groups (p > 0.05) (Table  3). Pocket 
closure was 78.1%, 76.7% and 74.4% in the probiotic, anti-
biotic and placebo group, without significant differences 
between the treatment modalities (p > 0.05) (Table 3).
The number of teeth and sites with PPD ≥ 5, ≥ 6 
and ≥ 7 mm were significantly reduced in all groups and 
without significant difference between the treatment 
modalities at 12  months follow-up (p > 0.05) (Table  4). 
While probiotics reduced the percentage of patients with 
PPD ≥ 5 mm and PPD ≥ 6 mm at 12 months, antibiotics 
reduced the percentage of patients with PPD ≥ 6 mm and 
PPD ≥ 7 mm (p < 0.025) (Additional file 1: Table S1).
The use of antibiotics significantly increased the num-
ber of patients with low risk for disease progression at 
12 months, and also significantly reduced the number of 
patients at higher risk for disease progression (Additional 
file  1: Table  S1). In addition, the antibiotic and placebo 
group showed at 12  months a reduced necessity for 
additional therapy in ≥ 3 sites but without significant 
differences between the both groups (Additional file  1: 
Table S1).
Discussion
This triple-blind placebo-controlled parallel-arm ran-
domized clinical trial evaluated the clinical effects of L. 
rhamnosus SP1 administered once a day for 3 months or 
azithromycin plus SRP in stage III periodontitis general-
ized grade B. The present study predominantly revealed: 
(1) a significant improvement of PPD and PI irrespec-
tive of the treatment modality and without significant 
differences between the groups; (2) no added benefit of 
probiotics or azithromycin in terms of CAL; (3) a sig-
nificant reduction in the number of sites and teeth with 
PPD ≥ 5, ≥ 6 and ≥ 7  mm in all groups at 12  month 
follow-up without differences between the treatment 
regimes. Therefore, the null hypothesis of the present 
study could not be rejected.
This is the first study evaluating and comparing the use 
of probiotics and antibiotics, in this case azithromycin, 
in the treatment of stage III periodontitis generalized 
Data presented as mean ± SD; BL: Baseline. CAL: Clinical attachment loss. PPD: Probing pocket depth
a Effect size of (∆3 months‐BL) was calculated by delta mean change from month 3 to baseline over standard deviation of baseline. bEffect size of (∆12 months‐BL) 
was calculated by delta mean change from month 12 to baseline over standard deviation of baseline
Intra-group comparison by Friedman test (p < 0.05) and Bonferroni-corrected Wilcoxon signed rank test (p < 0.025). Statistical significant in bold
Inter-group comparison by ANOVA and Kruskal Wallis test (p < 0.05)
Table 2 (continued)


























7.5 ± 1.0 7.4 ± 0.9 7.9 ± 1.2 0.1054 a > b 
(p = 0.0947)
− 0.4 ± 0.3 − 0.1 ± 0.3 − 0.4 ± 0.3 − 0.1 ± 0.3





7.5 ± 0.7 7.7 ± 0.7 7.1 ± 0.2 0.1054 a > b 
(p = 0.6845)
0.1 ± 1.4 − 0.2 ± 0.1 0.08 ± 1.1 − 0.2 ± 0.08





7.8 ± 0.7 7.6 ± 0.9 7.2 ± 0.2 0.6747 a > b 
(p = 0.3991)
− 0.6 ± 1.8 − 1.0 ± 1.0 − 0.4 ± 1.4 − 0.8 ± 0.8
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grade B with 1-year follow-up. In general, all treatment 
groups revealed a significant improvement in PPD, 
BOP, CAL and PI, however, without significant differ-
ences between the treatment modalities. Hence, these 
results failed to exhibit an added benefit of probiotics 
and azithromycin. With respect to probiotics, the pre-
sent results are in line with previous reports using pro-
biotics as an adjunct therapy to SRP for the management 
periodontitis. The administration of Lactobacillus reuteri 
DSM-17938 + ATCCPTA 5289 [27], Streptococcus ora-
lis KJ3 + Streptococcu uberis KJ2 + Streptococcu rattus 
JH145 [28] or L. rhamnosus SP1 [29] in conjunction with 
SRP did not enhance the clinical outcomes. Our observa-
tions are further supported by a very recent RCT which 
failed to demonstrate an additional clinical efficacy by the 
use of probiotics [30]. In that RCT, patients received L. 
reuteri ATCC PTA5289 twice a day in addition to SRP for 
28 days and the patients were recalled at 3 and 6 months. 
The use of probiotics failed to provide a clinical benefit 
compared to SRP alone. Our study revealed a reduc-
tion in the percentage of patients, teeth and sites with 
PPD ≥ 5 mm, ≥ 6 mm and ≥ 7 mm in all groups, however 
without inter-group differences. These observations are 
supported by previous reports indicating a lack of effect 
of probiotics [29, 30]. Overall, these findings, in addition 
to the results of the present study, suggest that probiotics 
may not provide an added benefit to SRP at least in this 
type of patient.
Our findings, on the other hand are in contrast to pre-
vious reports showing an added benefit of probiotics. 
Patients that received L. reuteri DSM-17938 + ATCCPTA 
5289 in conjunction to SRP showed a significantly higher 
PPD reduction along with a higher CAL gain at 12 month 
follow-up. Moreover, the probiotic group revealed a 
higher reduction of sites and patients with ≥ 6  mm [31] 
which could not be found in the present study. Outcomes 
from another report showed that patients who received 
L. reuteri ATCC 55,730 + ATCCPTA 5289 exhibited a 
higher reduction of CAL, PPD and BOP [32]. Similarly, 
the intake for 8 weeks of Lactobacillus salivarius WB21 
by patients with periodontitis significantly enhanced 
the reduction of PPD at two month follow-up [33]. Fur-
thermore, outcomes from a more recent RCT revealed a 
higher reduction of PPD and BOP by the use of L. reu-
teri lozenges  [34]. These positive results were corrobo-
rated by another group using Bifidobacterium animalis 
subsp. lactis HN019-showing improved PPD and CAL 
at 3  month follow-up [35]. This notable discrepancy 
with our findings might be attributed to the probiotic 
itself [36]. One might speculate that not all probiotics 
produce the same effect, particularly in addition to SRP. 
Moreover, other factors such as strain, concentration, 
vehicle and administration time of the probiotic might 
account for these divergent results. Indeed, the selection 
of the ‘‘best’’ probiotic for oral health is still a matter of 
debate. The selection of L. rhamnosus SP1 for the present 
study was based on the beneficial effects in the immune 
response of children and adults [37–39]. Presumably, this 
Table 3 Follow-up of  moderate (4–6  mm) and  deep 
pockets (≥ 7 mm) detected at baseline and pocket closure 
at 3- and 12- months follow up
Data presented as mean ± SD. PPD probing pocket depth
Inter-group comparison by ANOVA and Kruskal Wallis test (p < 0.05)
3 months 12 months
Follow-up of moderate pockets detected at 
baseline (%)
PPD ≤ 3 mm
 Probiotic group (n = 16) 68.5 ± 16.4 80.3 ± 18.3
 Antibiotic group (n = 16) 74.0 ± 13.7 77.8 ± 18.9
 Placebo group (n = 15) 77.0 ± 14.7 77.2 ± 14.5
 p value (inter‑group) 0.2877 0.6950
PPD 4–6 mm
 Probiotic group (n = 16) 30.3 ± 15.9 18.8 ± 17.6
 Antibiotic group (n = 16) 25.6 ± 13.0 20.9 ± 17.1
 Placebo group (n = 15) 21.5 ± 13.1 21.5 ± 13.4
 p value (inter‑group) 0.2391 0.7886
PPD ≥ 7 mm
 Probiotic group (n = 16) 1.2 ± 2.0 0.9 ± 2.3
 Antibiotic group (n = 16) 0.4 ± 1.4 1.3 ± 2.6
 Placebo group (n = 15) 1.5 ± 3.8 1.3 ± 3.8
 p value (inter‑group) 0.2861 0.8539
Follow-up of deep pockets detected at baseline 
(%)
PPD ≤ 3 mm
 Probiotic group (n = 16) 16.5 ± 28.5 42.4 ± 41.3
 Antibiotic group (n = 16) 33.0 ± 39.9 41.7 ± 43.9
 Placebo group (n = 15) 43.3 ± 38.7 38.8 ± 31.5
 p value (inter‑group) 0.2087 0.9798
PPD 4–6 mm
 Probiotic group (n = 16) 73.4 ± 30.9 47.0 ± 43.6
 Antibiotic group (n = 16) 50.2 ± 37.3 50.0 ± 41.6
 Placebo group (n = 15) 38.1 ± 28.1 45.9 ± 28.6
 p value (inter‑group) 0.1019 0.9715
PPD ≥ 7 mm
 Probiotic group (n = 16) 10.1 ± 17.7 10.6 ± 18.2
 Antibiotic group (n = 16) 16.8 ± 21.1 8.3 ± 18.0
 Placebo group (n = 15) 18.6 ± 26.6 15.3 ± 16.3
 p value (inter‑group) 0.6924 0.3030
Pocket closure (%)
 Probiotic group (n = 16) 65.3 ± 17.9 78.1 ± 20.0
 Antibiotic group (n = 16) 71.9 ± 14.4 76.7 ± 19.7
 Placebo group (n = 15) 73.3 ± 18.1 74.4 ± 16.8
 p value (inter‑group) 0.3790 0.6660
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Table 4 Teeth and sites with PPD ≥ 5, ≥ 6 and ≥ 7 mm at baseline, 3- and 6–12 months follow up






















33.3 ± 25.3 13.9 ± 12.5 9.7 ± 10.5 0.0040 a > b 
(p = 0.0009)
− 0.7 ± 0.7 − 0.9 ± 0.8 − 19.4 ± 18.1 − 23.5 ± 21.6




42.3 ± 24.1 12.7 ± 11.7 11.6 ± 11.6 0.0008 a > b 
(p = 0.0007)
− 1.1 ± 0.6 − 1.1 ± 0.7 − 28.5 ± 16.0 − 30.7 ± 18.9




46.4 ± 32.6 15.0 ± 21.1 15.2 ± 19.1 0.0034 a > b 
(p = 0.0007)
− 1.2 ± 0.9 − 1.2 ± 0.9 − 31.4 ± 25.3 − 31.2 ± 23.8




0.4163 0.8307 0.8075 0.1978 0.4069
Teeth with 




15.9 ± 15.4 6.4 ± 7.3 4.9 ± 6.2 0.0184 a > b 
(p = 0.0165)
− 0.5 ± 0.7 − 0.6 ± 0.7 − 9.6 ± 12.6 − 11.1 ± 13.8




16.7 ± 12.6 6.4 ± 8.2 5.5 ± 8.1 0.0014 a > b 
(p = 0.0009)
− 0.5 ± 0.5 − 0.6 ± 0.5 − 10.2 ± 8.8 − 11.2 ± 9.0




26.6 ± 25.8 8.4 ± 13.7 8.5 ± 12.2 0.0054 a > b 
(p = 0.0025)
− 1.0 ± 0.9 − 1.0 ± 1.0 − 18.2 ± 7.6 − 18.2 ± 18.4




0.6056 0.9650 0.6213 0.3702 0.2921
Teeth with 




8.3 ± 11.0 2.3 ± 2.9 1.8 ± 2.6 0.0490 a > b 
(p = 0.0738)
− 0.4 ± 0.7 − 0.5 ± 0.7 − 6.0 ± 9.7 − 6.5 ± 9.2




7.6 ± 7.6 3.0 ± 5.2 2.4 ± 4.7 0.0049 a > b 
(p = 0.0015)
− 0.4 ± 0.4 − 0.4 ± 0.5 − 5.1 ± 5.5 − 5.2 ± 7.1




16.1 ± 19.7 5.7 ± 8.9 5.1 ± 6.9 0.0469 a > b 
(p = 0.0122)
− 0.7 ± 0.9 − 0.8 ± 1.1 − 10.4 ± 13.1 − 11.0 ± 14.7




0.6573 0.8204 0.3481 0.6055 0.8091
Sites with 




10.9 ± 10.2 3.4 ± 3.6 2.4 ± 2.9 0.0043 a > b 
(p = 0.0013)
− 0.6 ± 0.6 − 0.7 ± 0.7 − 7.6 ± 7.9 − 8.5 ± 9.1
a > c 
(p = 0.0011)
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immune modulation elicited by the Lactobacillus strain 
might limit the detrimental immune response observed 
in periodontitis.
As for the use of azithromycin, the present results in 
general failed to show a clear clinical advantage over 
SRP and placebo. These findings are in accordance 
with previously published data where a clinical benefit 
of azithromycin in conjunction with SRP could not be 
determined [22, 40, 41]. This lack of additional benefit 
of azithromycin is in direct contrast with the conclu-
sions of a recent systematic review with meta-analysis 
[42]. These differences might be attributed to the higher 
Table 4 (continued)



















14.1 ± 8.9 3.6 ± 4.3 3.3 ± 4.0 0.0005 a > b 
(p = 0.0007)
− 0.8 ± 0.4 − 0.8 ± 0.5 − 10.2 ± 5.7 − 10.8 ± 6.6




20.0 ± 18.6 4.8 ± 7.2 4.3 ± 6.1 0.0019 a > b 
(p = 0.0007)
− 1.1 ± 1.1 − 1.2 ± 1.1 − 15.2 ± 14.6 − 15.7 ± 14.9




0.3755 0.8940 0.8700 0.2328 0.3160
Sites with 




4.3 ± 4.7 1.4 ± 1.7 1.2 ± 2.0 0.0180 a > b 
(p = 0.0215)
− 0.4 ± 0.5 − 0.4 ± 0.5 − 2.9 ± 3.7 − 3.1 ± 4.1




4.9 ± 4.4 1.6 ± 2.7 1.3 ± 2.1 0.0049 a > b 
(p = 0.0009)
− 0.4 ± 0.3 0.4 ± 0.4 − 3.5 ± 2.6 − 3.6 ± 3.6




10.2 ± 11.3 2.2 ± 3.5 2.1 ± 3.1 0.0013 a > b 
(p = 0.0030)
− 1.0 ± 1.1 − 1.0 ± 1.2 − 8.0 ± 9.1 − 8.1 ± 9.3




0.4818 0.9371 0.6105 0.3637 0.4272
Sites with 




1.8 ± 2.6 0.6 ± 1.0 0.6 ± 1.4 0.0407 a > b 
(p = 0.0738)
− 0.3 ± 0.5 − 0.3 ± 0.5 − 1.2 ± 1.9 − 1.2 ± 1.9




1.9 ± 2.1 0.6 ± 1.3 0.6 ± 1.2 0.0042 a > b 
(p = 0.0016)
− 0.4 ± 0.4 − 0.3 ± 0.4 − 1.4 ± 1.6 − 1.4 ± 1.7




4.7 ± 6.8 1.4 ± 2.4 1.1 ± 1.8 0.0423 a > b 
(p = 0.0198)
− 0.8 ± 1.4 − 0.9 ± 1.5 − 3.3 ± 5.5 − 3.6 ± 6.0




0.5671 0.8492 0.4180 0.5396 0.7226
Note: Data presented as mean ± SD of percentages. BL baseline, PPD probing pocket depth
a Effect size of (∆3 months‐BL) was calculated by delta mean change from month 3 to baseline over standard deviation of baseline. bEffect size of (∆12 months‐BL) 
was calculated by delta mean change from month 12 to baseline over standard deviation of baseline
Intra-group comparison by Friedman test (p < 0.05) and Bonferroni-corrected Wilcoxon signed rank test (p < 0.025). Statistical significant in bold
Inter-group comparison by ANOVA and Kruskal Wallis test (p < 0.05)
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potential of meta-analysis to estimate an overall mean 
effect. Indeed, we found a significant reduction in the 
number of patients with PPD ≥ 7  mm in the azithro-
mycin group, however this difference was not robust 
enough to show a significant benefit compared to the 
other groups. It has been suggested that azithromycin 
produces some minor benefits. In this regard, it should 
be noted that the inclusion of 3 treatment groups along 
with the corresponding correction for multiple compar-
ison may have influenced the power to find minor dif-
ferences between the groups. Thus, azithromycin may 
produce some benefits but they could not be detected 
by our clinical trial. A recent systematic review under-
lined that the reported clinical advantage of azithromy-
cin should be interpreted with caution since the major 
effect was derived from a single study [42] with a high 
risk of bias.
We recognize that this study has a number of limita-
tions. First, the small sample size. Although a sample size 
calculation was performed, a larger sample size would 
allow for the detection of smaller differences between 
the adjunctive therapeutic agents. However, it should be 
noted that there is no consensus from which point a sta-
tistical difference is clinically relevant. Second, microbio-
logical and samples were not taken, therefore it is unclear 
whether the probiotics triggered a microbial shift. In this 
sense, whether the probiotic bacteria actually colonized 
the oral cavity remains to be elucidated. Third, since the 
present study only included patients with stage III peri-
odontitis grade B, the effect of probiotics or azithromycin 
on other stages and grades of periodontitis has yet to be 
determined.Future studies should include larger popula-
tions in different stages and grades of periodontitis.
Conclusion
In conclusion and within the limitations of the present 
study, the administration of L. rhamnosus SP1 or azithro-
mycin in the treatment of stage III periodontitis general-
ized grade B failed to produce additional beneficial effects 
when compared to SRP on its own. Given the lack of ben-
efits and the conflicting data in the literature, the benefits 
of probiotics and azithromycin as an adjunct to SRP in 
the treatment of periodontitis remains unclear.
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